Blood Sampling of Healthy Volunteers for Immunological Research
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Healthy Volunteers
- Sponsor
- The Netherlands Cancer Institute
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- The number of immune cells, both lymphoid and myeloid, present in the blood of healthy individuals, assessed by flow cytometry, as well as cytokine expression and transcriptome profiles of these cells
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This protocol will be used to collect crucial components of the immune system from healthy volunteers for the characterization of immune cells in fresh blood. A pipeline has been set up for comprehensive immune phenotyping of both lymphoid and myeloid cells within 24 hours after blood withdrawal.
Detailed Description
In order to properly compare the immunobiology of healthy volunteers to (advanced) cancer patients, the investigators use age-matched controls with no history of cancer and no potentially interfering medication. Healthy volunteers will be asked to donate 5 tubes of blood
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age above 35 years
- •Written informed consent
- •No history of cancer
- •No use of systemic immunosuppressive medication (eg. corticosteroids). Local use of corticosteroids (eg. topical or inhalation) is allowed.
Exclusion Criteria
- •Fever 14 days before blood withdrawal
- •Donated blood for the same program within the last 2 years
- •Pregnancy
Outcomes
Primary Outcomes
The number of immune cells, both lymphoid and myeloid, present in the blood of healthy individuals, assessed by flow cytometry, as well as cytokine expression and transcriptome profiles of these cells
Time Frame: assessed up to 12 months
the number of lymphoid and myeloid immune cells present in the blood of healthy individuals using flow cytometry, assessing the cytokine expression of these cells in healthy individuals using ELISA cytokine assays, and assessing gene expression of these cells using single cell transcriptomics analyses using droplet-based single cell RNA sequencing.
Secondary Outcomes
- Immunophenotyping of both myeloid and lymphoid cells in healthy individuals(assessed up to 12 months)